EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer

Mari Iida iD, Bridget E Crossman iD, Kourtney L Kostecki iD, Christine E Glitchev, Carlene A Kranjac, Madisen T Crow, Jillian M Adams, Peng Liu, Irene Ong, David T Yang iD, Irene Kang, Ravi Salgia iD und 1 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25105109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mari Iida und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Oncology, University of Wisconsin-Madison, Madison, WI 53705, USA. Hauptthemen laut MEDLINE: c-Mer Tyrosine Kinase, Triple Negative Breast Neoplasms, Cell Proliferation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, University of Wisconsin Carbone Cancer Center (UWCCC) Breast DOT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is characterized by the absence of the estrogen receptor, progesterone receptor, and receptor tyrosine kinase HER2 expression. Due to the limited number of FDA-approved targeted therapies for TNBC, there is an ongoing need to understand the molecular underpinnings of TNBC for the development of novel combinatorial treatment strategies. This study evaluated the role of the MerTK receptor tyrosine kinase on proliferation and invasion/metastatic potential in TNBC. Immunohistochemical analysis demonstrated MerTK expression in 58% of patient-derived TNBC xenografts. The stable overexpression of MerTK in human TNBC cell lines induced an increase in proliferation rates, robust in vivo tumor growth, heightened migration/invasion potential, and enhanced lung metastases. NanoString nCounter analysis of MerTK-overexpressing SUM102 cells (SUM102-MerTK) revealed upregulation of several signaling pathways, which ultimately drive cell cycle progression, reduce apoptosis, and enhance cell survival. Proteomic profiling indicated increased endoglin (ENG) production in SUM102-MerTK clones, suggesting that MerTK creates a conducive environment for increased proliferative and metastatic activity via elevated ENG expression. To determine ENG’s role in increasing proliferation and/or metastatic potential, we knocked out ENG in a SUM102-MerTK clone with CRISPR technology. Although this ENG knockout clone exhibited similar in vivo growth to the parental SUM102-MerTK clone, lung metastasis numbers were significantly decreased ~4-fold, indicating that MerTK enhances invasion and metastasis through ENG. Our data suggest that MerTK regulates a unique proliferative signature in TNBC, promoting robust tumor growth and increased metastatic potential through ENG upregulation. Targeting MerTK and ENG simultaneously may provide a novel therapeutic approach for TNBC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

c-Mer Tyrosine KinaseTriple Negative Breast NeoplasmsCell ProliferationHumansAnimalsFemaleMiceCell Line, TumorCell MovementGene Expression Regulation, NeoplasticEndoglinLung NeoplasmsNeoplasm MetastasisSignal TransductionApoptosis

Stichwörter der Autor:innen

MerTKTNBCendoglinlung metastases

Substanzen

c-Mer Tyrosine KinaseMERTK protein, humanEndoglin

Autor:innen und Institutionen

  • Department of Human Oncology, University of Wisconsin-Madison, Madison, WI 53705, USA.
  • Departments of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI 53726, USA.
  • Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53792, USA.
  • Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, WI 53705, USA.
  • Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.
  • Department of Medical Oncology and Experimental Therapeutics, Comprehensive Cancer Center, City of Hope, Duarte, CA 91010, USA.

ORCID-Profile: Mari Iida, Bridget E Crossman, Kourtney L Kostecki, David T Yang, Ravi Salgia

Förderung

  • NCI NIH HHS
  • NIH HHS
  • University of Wisconsin Carbone Cancer Center (UWCCC) Breast DOT
  • NIH/NCI
  • Office of the Director—NIH

Zitieren

APA

Iida, M., Crossman, B. E., Kostecki, K. L., Glitchev, C. E., Kranjac, C. A., Crow, M. T., Adams, J. M., Liu, P., Ong, I., Yang, D. T., Kang, I., Salgia, R., & Wheeler, D. L. (2024). MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105109

Vancouver

Iida M, Crossman BE, Kostecki KL, Glitchev CE, Kranjac CA, Crow MT, et al. MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105109

BibTeX
@article{Iida2024,
  author = {Iida, Mari and Crossman, Bridget E and Kostecki, Kourtney L and Glitchev, Christine E and Kranjac, Carlene A and Crow, Madisen T and Adams, Jillian M and Liu, Peng and Ong, Irene and Yang, David T and Kang, Irene and Salgia, Ravi and Wheeler, Deric L},
  title = {MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25105109}
}
Kostenlos starten →